Horizon has entered into a number of partnerships to expand its product and service offerings and to insure that it's technologies are available globally.
H3 Biomedicine Inc. is a biopharmaceutical company specializing in the discovery and development of oncology treatments.
Horizon is working with H3 Biomedicine to identify and validate critical cancer genome targets whose modulation will have meaningful clinical effect. Based on targets validated in partnership with Horizon, H3 Biomedicine will then carry out early target discovery through to preclinical research and the clinical research (via Eisai Pharmaceuticals), while Horizon will continue to implement its discovery toolbox to run alongside and support H3 Biomedicine’s internal research programs.
Promega is a leader in providing innovative solutions and technical support to the life sciences industry offering more than 2,000 products enable scientists worldwide to advance their research in genomics, proteomics, and cellular analysis.
The objective of the partnership is to develop new endogenous pathway imaging and reporter models by incorporating Promega’s NanoLuc™ and HaloTag® technologies into X-MAN™ cell lines to generate unique screening tools that exploit the ability to monitor the activity levels and localisation of specific genes and proteins in live cells at the endogenous level.
The first 30 assay kits are being launched in Q4, 2012.
ATCC is a private, non-profit biological resource center and research organization whose mission focuses on the acquisition, authentication and production of cell lines.
Horizon’s partnership with ATCC is based on the provision of X-MAN isogenic cell lines through ATCC to their large academic client base in conjunction with their established sold tumor cancer panels thus significantly extending the reach of X-MAN cell lines into academic research.
SPI is a wholly owned subsidiary of Sumitomo Corporation and is an integrated service company specializing in the area of pharmaceutical development and commercialization.
Horizon has entered into an agreement with SPI to identify business opportunities in Japan.
Crown Bioscience Inc. is a contract research service company focused on advancing anti-cancer therapeutics through the preclinical and drug development stages.
The partnership between Horizon and Crownbio will allow their xenograft and other pre-clinical cancer models to exploit the genetic definition of Horizon’s X-MAN™ isogenic cell lines in vivo, to the benefit of customers of both companies.
The European Molecular Genetics Quality Network (EMQN) is a provider of External Quality Assessment (EQA) services which are essential for any laboratory seeking to maintain and provide a quality service.
Horizon provides genetically defined isogenic human cell line reference standards, in carefully calibrated and quality controlled mutant vs. normal stochiometries, for distribution to molecular diagnostic laboratories around the world as part of EMQN’s annual EQA schemes.
UK NEQAS ICC (the UK National External Quality Assessment Service) is a leader in diagnostic proficiency assessment. They ensure optimal patient care by providing a comprehensive external quality assessment service in laboratory medicine.
UK NEQAS ICC receives an exclusive license to distribute isogenic reference standards related to certain lung cancer biomarkers in the UK and in Europe for the sole purpose of proficiency testing within its quality assessment program.
EntroGen, Inc is a bio-technology company developing novel genotyping assays in the areas of pharmacogenomics and oncology.
Horizon has developed a range of key FFPE-based isogenic reference standards that are assisting with the development of EntroGen’s molecular assays.
The University of Torino is a key partner along with Horizon in COLTHERES, a consortium of EU-clinical centers and translational researchers. Professor Alberto Bardelli from the University of Torino School of Medicine in Turin, and co-founder of Horizon Discovery, is lead investigator for the Consortium.
COLTHERES is a four-year program that will use comprehensively molecularly-annotated colon cancers as a ‘test-bed’ to define specific biomarkers of response or resistance to signalling pathway agents.
Horizon Discovery and the Institute of Cancer Research have formed a collaboration aimed at rapidly screening the human genome for novel drug targets that selectively kill cancer cells.
ICR scientist Professor Alan Ashworth, Director of the Breakthrough Breast Cancer Research Center at the ICR, has previously demonstrated the concept of ‘synthetic lethality’ which is now being applied to Horizon’s SyntheTx high-throughput screening platform.
Horizon has a commercial agreement with Novartis Institute of Biomedical Research relating to the ongoing access to a panel of X-MAN™ cell lines. The collaboration between the companies, which began in November 2009, and successfully completed an 18 month pilot program in 2011 has now been progressed to generate 30-50 new X-MAN cell lines annually.
Horizon has a long history of working with key researchers at Johns Hopkins University in the area of rAAV gene-editing technology. Dr. Bert Vogelstein is the source of many of Horizon’s initial set of cell lines, and Dr. Ben Ho Park is working with Horizon on drug repositioning and acts as an advisor through our S.A.B.
Horizon and the lab of Steve Jackson at the Gurdon Institute in the University of Cambridge are working together to create isogenic cell line models using Horizon’s rAAV gene-editing technology to create endogenous gene tags/ knockouts/ mutations as part of Horizon’s Centers of Excellence program.
The focus of the Jackson lab is to better understand how cells detect DNA damage and signal its presence to the DNA repair, transcription and cell cycle machineries. Loss of these pathways is important in many diseases including sporadic and hereditary cancer.
Horizon has an extensive collaboration with Washington University St Louis, one of Horizon’s premier Centers of Excellence. Washington University is establishing a core facility that will create isogenic cell lines using rAAV that will benefit a number of academic groups at the university.
This facility will also be able to use rAAV to translate information that arises from genomic studies on specific diseases, such as cancer, performed at the BRIGHT Institute at Washington University into endogenous cell line models.
Paragraph explaining benefits of Biocair×